Stock Alert for Molecular Insight Pharmaceuticals Inc. Issued by MicroStockProfit
16 6월 2010 - 7:50PM
MicroStockProfit.com announces an investment report featuring
Molecular Insight Pharmaceuticals Inc. (Nasdaq:MIPI). The
report includes financial, comparative and investment analyses, and
industry information you need to know to make an educated
investment decision.
The full report is available at:
www.microstockprofit.com/lp/MIPI
Molecular Insight Pharmaceuticals Inc. (MIPI), a clinical-stage
biopharmaceutical company, focuses on the discovery, development
and commercialization of targeted therapeutic and imaging
radiopharmaceuticals for use in oncology. The Company has
five clinical-stage candidates in development. Its lead oncology
product candidates include Azedra, Onalta, Trofex and Solazed.
Azedra and Onalta are being developed for the treatment of
neuroendocrine cancers; Trofex is being developed for the detection
of metastatic prostate cancer, and Solazed is being developed for
the treatment of metastatic melanoma. Its non-oncology product
candidate, Zemiva, is being developed for the diagnosis of cardiac
ischemia (insufficient blood flow to the heart muscle).
Message Board Search for MIPI:
http://www.boardcentral.com/boards/MIPI
In the report, the analyst notes:
"MIPI last week released a press release noting its presentation
at the Nuclear Medicine 2010 meeting in Salt Lake City. The
Company said it presented nonclinical data demonstrating the
utility of its novel radiopharmaceutical compounds for the
molecular imaging of prostate and other tumors.
"MIPI also announced the receipt of SNM's 2010 Berson-Yalow
Award for a nonclinical study demonstrating the potential of the
Company's compound 99mTc-MIP-1340 to provide accurate imaging of
metastatic prostate cancer. The Berson-Yalow Award honors
originality and research that makes the most significant
contributions to basic or clinical radioassay science."
To read the entire report visit:
www.microstockprofit.com/lp/MIPI.
See what investors are saying about MIPI at penny stock
forum
MicroStockProfit.com is a small-cap research and investment
commentary provider. MicroStockProfit.com strives to provide
a balanced view of many promising small-cap companies that would
otherwise fall under the radar of the typical Wall Street
investor. We provide investors with an excellent first step
in their research and due diligence by providing daily trading
ideas, and consolidating the public information available on
them. For more information on MicroStockProfit please visit:
http://www.microstockprofit.com.
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and
nothing contained in any materials should be construed as a
recommendation to buy or sell any securities.
MicroStockProfit.com is a Web site wholly owned by BlueWave
Advisors, LLC. Neither MicroStockProfit.com nor its
affiliates have a beneficial interest in the mentioned company; nor
have they received compensation of any kind for any of the
companies listed in this communication. Please read our
report and visit our Web site, MicroStockProfit.com, for complete
risks and disclosures.
CONTACT: MicroStockProfit.com
Brian Johnson
1-888-307-2850
info@microstockprofit.com
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 12월(12) 2024
Molecular Insight Pharmaceuticals (MM) (NASDAQ:MIPI)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024